세계의 발열성 호중구 감소증 시장 보고서(2025년)

Febrile Neutropenia Global Market Report 2025

US $ 4,490 ￦ 6,342,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,167,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,992,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

발열성 호중구 감소증 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 6.4%로 성장할 전망이며, 144억 8,000만 달러로 성장이 예측됩니다. 예측 기간 동안의 성장은 면역억제제 사용 확대, 연구개발(R&D) 증가, 유리한 상환정책, 투자 증가, 백혈병 환자 증가 등의 요인에 의한 것으로 보입니다. 이 기간 주요 동향으로는 신속한 분자진단, 항균제 스튜어드십 및 탈스케일링 요법 채택, 면역요법 및 표적치료, 위험층별화 모델 개발, 진균 바이오마커의 진보 등이 있습니다.

암의 유병률 증가는 향후 수년간 발열성 호중구 감소증 시장의 성장을 견인할 것으로 예측됩니다. 암은 가까운 조직에 침입하여 전신에 퍼질 수 있는 이상 세포의 제어 불가능한 증식으로 특징지어지는 복잡한 일련의 질환입니다. 암의 이환율 상승은 고령화, 환경 및 직업상의 노출, 유전적 소인, 호르몬 및 생식 인자 등의 요인에 의한 바가 큽니다. 발열성 호중구 감소증은 화학요법 중 감염 위험의 상승을 강조하고 조기 개입을 촉진하여 생명을 위협하는 합병증을 예방하기 위한 표적 치료를 가능하게 함으로써 암환자를 지원하는데 중요한 역할을 하고 있습니다. 이를 통해 환자의 전귀를 개선하고 암 치료를 적시에 계속할 수 있습니다. 예를 들어 2022년 1월 미국암협회는 미국에서는 새로 190만 명의 암 환자와 60만 9,360명의 암 관련 죽음이 예상되며 매일 1,670명 가까이 사망하고 있다고 보고했습니다. 따라서 암 유병률의 증가가 발열성 호중구 감소증 시장의 성장을 촉진하고 있습니다.

발열성 호중구 감소증 시장의 주요 기업은 치료에 대한 접근성을 높이기 위해 첨단 바이오시밀러 의약품 개발에 주력하고 있습니다. 바이오시밀러 의약품은 구조, 기능, 효능에서 승인된 참조의약품을 충실히 반영한 생물제제입니다. 바이오시밀러 의약품은 오리지널 생물제제를 대체할 수 있는 비용대비 효과가 높은 대체품을 제공하고 엄격한 규제기준을 준수하면서 환자 접근성을 향상시킵니다. 예를 들어 독일에 본사를 둔 제약회사 프레제니우스 카비는 2022년 9월 바이오시밀러인 Stimufend(pegfilgrastim-fpgk)에 대해 미국 식품의약국(FDA)의 승인을 취득했습니다. 이 승인으로 골수억제적 화학 요법을 받고 있는 비골수성 악성종양 환자에서 백혈구 수의 저하와 발열을 특징으로 하는 발열성 호중구 감소증을 일으킬 수 있는 Stimufend 사용이 가능해졌습니다. 이 회사는 프리필드 주사기 타입의 Stimufend를 2023년 초에 출시할 예정이며, 향후 사용을 위해 체내 주사기도 개발 중입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 발열성 호중구 감소증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 발열성 호중구 감소증 시장 : 성장률 분석
• 세계의 발열성 호중구 감소증 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 발열성 호중구 감소증 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 발열성 호중구 감소증 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 발열성 호중구 감소증 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 경험적 항생제 요법
• 표적 항생제 요법
• 지지 요법
• 세계의 발열성 호중구 감소증 시장 : 리스크 요인별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 화학요법 유발성 호중구 감소증
• 이식 관련 호중구 감소증
• 유전성 질환
• 세계의 발열성 호중구 감소증 시장 : 병인별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 그람 음성 세균
• 그람 양성 세균
• 곰팡이 감염증
• 바이러스 감염
• 세계의 발열성 호중구 감소증 시장 : 진단 방법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 혈액 배양
• 화상 검사
• 골수 천자
• 세계 발열성 호중구 감소증 시장 : 경험적 항생제 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 광역 스펙트럼 β-락탐
• 당 펩티드
• 카르바페넴
• 세계 발열성 호중구 감소증 시장 : 표적 항생제 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 항진균 요법
• 항바이러스 요법
• 그람 양성 세균 요법
• 그람 음성 세균 요법
• 세계의 발열성 호중구 감소증 시장 : 지지 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 과립구 콜로니 자극 인자(G-CSF)
• 정맥 내 주입
• 해열제와 통증 관리

제7장 지역별 및 국가별 분석

• 세계의 발열성 호중구 감소증 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 발열성 호중구 감소증 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

• 발열성 호중구 감소증 시장 : 경쟁 구도
• 발열성 호중구 감소증 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
  • Amgen Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Teva Pharmaceutical Industries Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sandoz 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Fresenius Kabi
• Aurobindo Pharma Ltd.
• Lupin Limited
• Mundipharma GmbH
• BeyondSpring Inc.
• Hospira Inc.
• Biocon Biologics Limited
• Kyowa Kirin Co. Ltd.
• Coherus BioSciences Inc.
• Assertio Holdings Inc.
• Napp Pharmaceuticals Limited
• Gennova Biopharmaceuticals Limited
• Acrotech Biopharma Inc.
• Taiho Pharmaceutical Co. Ltd.
• Evive Biotech

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

• 발열성 호중구 감소증 시장(2029년) : 새로운 기회를 제공하는 국가
• 발열성 호중구 감소증 시장(2029년) : 새로운 기회를 제공하는 부문
• 발열성 호중구 감소증 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

AJY

영문 목차

영문목차

Febrile neutropenia is a medical condition characterized by a fever (a temperature of 100.4°F or higher) and a low count of neutrophils, which are essential white blood cells needed to fight infections. This condition is commonly seen in patients undergoing chemotherapy or other treatments that suppress the immune system, making them more susceptible to infections.

The main treatment approaches for febrile neutropenia include empirical antibiotic therapy, targeted antibiotic therapy, and supportive care. Empirical antibiotic therapy involves initiating treatment with broad-spectrum antibiotics based on clinical assessment before identifying the exact causative pathogen. The condition is associated with various risk factors, such as chemotherapy-induced neutropenia, transplant-related neutropenia, and genetic disorders, with several potential etiologies including gram-negative bacteria, gram-positive bacteria, fungal infections, and viral infections. Diagnosis is made using various methods, such as blood cultures, imaging tests, and bone marrow aspiration.

The febrile neutropenia market research report is one of a series of new reports from The Business Research Company that provides febrile neutropenia market statistics, including the febrile neutropenia industry global market size, regional shares, competitors with the febrile neutropenia market share, detailed febrile neutropenia market segments, market trends, and opportunities, and any further data you may need to thrive in the febrile neutropenia industry. This febrile neutropenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The febrile neutropenia market size has grown strongly in recent years. It will grow from $10.60 billion in 2024 to $11.31 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth during the historic period can be attributed to factors such as the rising incidence of cancer, the growing adoption of chemotherapy, the expansion of personalized medicine, efforts to reduce healthcare costs, and the increasing prevalence of neutropenia.

The febrile neutropenia market size is expected to see strong growth in the next few years. It will grow to $14.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth during the forecast period can be attributed to factors such as the growing use of immunosuppressive drugs, increasing research and development (R&D), favorable reimbursement policies, rising investments, and the increasing incidence of leukemia cases. Key trends during this period include rapid molecular diagnostics, the adoption of antimicrobial stewardship and de-escalation therapy, immunotherapy and targeted treatments, the development of risk stratification models, and advancements in fungal biomarkers.

The growing prevalence of cancer is expected to drive the growth of the febrile neutropenia market in the coming years. Cancer is a complex set of diseases marked by the uncontrolled growth of abnormal cells that can invade nearby tissues and spread throughout the body. The rising incidence of cancer is largely due to factors such as an aging population, environmental and occupational exposures, genetic predisposition, and hormonal and reproductive factors. Febrile neutropenia plays a critical role in supporting cancer patients by highlighting the increased risk of infections during chemotherapy, encouraging early intervention, and enabling targeted treatments to prevent life-threatening complications. This helps improve patient outcomes and ensures timely continuation of cancer therapies. For example, in January 2022, the American Cancer Society reported that in the U.S., an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths were expected, with nearly 1,670 deaths occurring daily. Therefore, the increasing prevalence of cancer is driving the growth of the febrile neutropenia market.

Key players in the febrile neutropenia market are focusing on the development of advanced biosimilar drugs to increase treatment accessibility. Biosimilar drugs are biologics that closely mirror approved reference drugs in structure, function, and efficacy. They provide cost-effective alternatives to original biologics, improving patient access while complying with stringent regulatory standards. For instance, in September 2022, Fresenius Kabi, a Germany-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for its biosimilar Stimufend (pegfilgrastim-fpgk). This approval allows Stimufend to be used in patients with non-myeloid malignancies who are undergoing myelosuppressive chemotherapy, which can lead to febrile neutropenia, a condition characterized by a low white blood cell count and fever. The company plans to launch Stimufend in a prefilled syringe format in early 2023 and is also developing an on-body injector for future use.

In July 2023, Assertio Holdings Inc., a U.S.-based pharmaceutical company, acquired Spectrum Pharmaceuticals for an undisclosed amount. This acquisition is aimed at expanding and diversifying Assertio's revenue base, enhancing its oncology portfolio with ROLVEDON (eflapegrastim-xnst) injection, and strengthening its commercial and digital marketing capabilities. Spectrum Pharmaceuticals is a U.S.-based company specializing in the manufacture of febrile neutropenia drugs.

Major players in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz, Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Mundipharma GmbH, BeyondSpring Inc., Hospira Inc., Biocon Biologics Limited, Kyowa Kirin Co. Ltd., Coherus BioSciences Inc., Assertio Holdings Inc., Napp Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited, Acrotech Biopharma Inc., Taiho Pharmaceutical Co. Ltd., Evive Biotech.

North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the febrile neutropenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The febrile neutropenia market consists of revenues earned by entities by providing services such as diagnostic services, hematologic support, hospitalization and monitoring, and outpatient management. The market value includes the value of related goods sold by the service provider or included within the service offering. The febrile neutropenia market also includes sales of antibiotics, antifungal and antiviral medications, urinalysis, and urine culture. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Febrile Neutropenia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on febrile neutropenia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for febrile neutropenia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The febrile neutropenia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Empirical Antibiotic Therapy; Targeted Antibiotic Therapy; Supportive Care
• 2) By Risk Factors: Chemotherapy-Induced Neutropenia; Transplant-Related Neutropenia; Genetic Disorders
• 3) By Etiology: Gram-Negative Bacteria; Gram-Positive Bacteria; Fungal Infections; Viral Infections
• 4) By Diagnostic Methods: Blood Cultures; Imaging Tests; Bone Marrow Aspiration
• Subsegments:
• 1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams; Glycopeptides; Carbapenems
• 2) By Targeted Antibiotic Therapy: Antifungal Therapy; Antiviral Therapy; Gram-Positive Bacterial Therapy; Gram-Negative Bacterial Therapy
• 3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs); Intravenous Fluids; Antipyretics And Pain Management
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Sandoz
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Febrile Neutropenia Market Characteristics

3. Febrile Neutropenia Market Trends And Strategies

4. Febrile Neutropenia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Febrile Neutropenia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Febrile Neutropenia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Febrile Neutropenia Market Growth Rate Analysis
• 5.4. Global Febrile Neutropenia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Febrile Neutropenia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Febrile Neutropenia Total Addressable Market (TAM)

6. Febrile Neutropenia Market Segmentation

• 6.1. Global Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Empirical Antibiotic Therapy
• Targeted Antibiotic Therapy
• Supportive Care
• 6.2. Global Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy-Induced Neutropenia
• Transplant-Related Neutropenia
• Genetic Disorders
• 6.3. Global Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gram-Negative Bacteria
• Gram-Positive Bacteria
• Fungal Infections
• Viral Infections
• 6.4. Global Febrile Neutropenia Market, Segmentation By Diagnostic Methods, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Cultures
• Imaging Tests
• Bone Marrow Aspiration
• 6.5. Global Febrile Neutropenia Market, Sub-Segmentation Of Empirical Antibiotic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Broad-Spectrum Beta-Lactams
• Glycopeptides
• Carbapenems
• 6.6. Global Febrile Neutropenia Market, Sub-Segmentation Of Targeted Antibiotic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antifungal Therapy
• Antiviral Therapy
• Gram-Positive Bacterial Therapy
• Gram-Negative Bacterial Therapy
• 6.7. Global Febrile Neutropenia Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Granulocyte Colony-Stimulating Factors (G-CSFs)
• Intravenous Fluids
• Antipyretics And Pain Management

7. Febrile Neutropenia Market Regional And Country Analysis

• 7.1. Global Febrile Neutropenia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Febrile Neutropenia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Febrile Neutropenia Market

• 8.1. Asia-Pacific Febrile Neutropenia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Febrile Neutropenia Market

• 9.1. China Febrile Neutropenia Market Overview
• 9.2. China Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Febrile Neutropenia Market

• 10.1. India Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Febrile Neutropenia Market

• 11.1. Japan Febrile Neutropenia Market Overview
• 11.2. Japan Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Febrile Neutropenia Market

• 12.1. Australia Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Febrile Neutropenia Market

• 13.1. Indonesia Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Febrile Neutropenia Market

• 14.1. South Korea Febrile Neutropenia Market Overview
• 14.2. South Korea Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Febrile Neutropenia Market

• 15.1. Western Europe Febrile Neutropenia Market Overview
• 15.2. Western Europe Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Febrile Neutropenia Market

• 16.1. UK Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Febrile Neutropenia Market

• 17.1. Germany Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Febrile Neutropenia Market

• 18.1. France Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Febrile Neutropenia Market

• 19.1. Italy Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Febrile Neutropenia Market

• 20.1. Spain Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Febrile Neutropenia Market

• 21.1. Eastern Europe Febrile Neutropenia Market Overview
• 21.2. Eastern Europe Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Febrile Neutropenia Market

• 22.1. Russia Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Febrile Neutropenia Market

• 23.1. North America Febrile Neutropenia Market Overview
• 23.2. North America Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Febrile Neutropenia Market

• 24.1. USA Febrile Neutropenia Market Overview
• 24.2. USA Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Febrile Neutropenia Market

• 25.1. Canada Febrile Neutropenia Market Overview
• 25.2. Canada Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Febrile Neutropenia Market

• 26.1. South America Febrile Neutropenia Market Overview
• 26.2. South America Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Febrile Neutropenia Market

• 27.1. Brazil Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Febrile Neutropenia Market

• 28.1. Middle East Febrile Neutropenia Market Overview
• 28.2. Middle East Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Febrile Neutropenia Market

• 29.1. Africa Febrile Neutropenia Market Overview
• 29.2. Africa Febrile Neutropenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Febrile Neutropenia Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Febrile Neutropenia Market, Segmentation By Etiology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Febrile Neutropenia Market Competitive Landscape And Company Profiles

• 30.1. Febrile Neutropenia Market Competitive Landscape
• 30.2. Febrile Neutropenia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sandoz Overview, Products and Services, Strategy and Financial Analysis

31. Febrile Neutropenia Market Other Major And Innovative Companies

• 31.1. Fresenius Kabi
• 31.2. Aurobindo Pharma Ltd.
• 31.3. Lupin Limited
• 31.4. Mundipharma GmbH
• 31.5. BeyondSpring Inc.
• 31.6. Hospira Inc.
• 31.7. Biocon Biologics Limited
• 31.8. Kyowa Kirin Co. Ltd.
• 31.9. Coherus BioSciences Inc.
• 31.10. Assertio Holdings Inc.
• 31.11. Napp Pharmaceuticals Limited
• 31.12. Gennova Biopharmaceuticals Limited
• 31.13. Acrotech Biopharma Inc.
• 31.14. Taiho Pharmaceutical Co. Ltd.
• 31.15. Evive Biotech

32. Global Febrile Neutropenia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Febrile Neutropenia Market

34. Recent Developments In The Febrile Neutropenia Market

35. Febrile Neutropenia Market High Potential Countries, Segments and Strategies

• 35.1 Febrile Neutropenia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Febrile Neutropenia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Febrile Neutropenia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료